ZNF684 expression based on
PAAD : Pancreatic adenocarcinoma *
Please note that low number(<10) of normal samples considered.
Comparison Statistical significance Normal-vs-Primary 2.972500E-04
Pan-cancer view
Methylation
Survival
Correlated genes
DepMap
PAAD : Pancreatic adenocarcinoma *
Please note that low number(<10) of normal samples considered.
Note
Cancer stage information is not available for 3 samples.
Show statistics
Hide statistics
Comparison Statistical significance
Normal-vs-Stage1
1.573960E-01
Normal-vs-Stage2
2.211200E-04
Normal-vs-Stage3
3.355700E-04
Normal-vs-Stage4
2.284200E-02
Stage1-vs-Stage2
4.514100E-02
Stage1-vs-Stage3
4.540100E-02
Stage1-vs-Stage4
3.962200E-01
Stage2-vs-Stage3
8.607600E-02
Stage2-vs-Stage4
1.098460E-03
Stage3-vs-Stage4
1.287910E-02
Pan-cancer view
Methylation
Survival
Correlated genes
DepMap
PAAD : Pancreatic adenocarcinoma *
Please note that low number(<10) of normal samples considered.
Note
Patient race information is not available for 5 samples.
Show statistics
Hide statistics
Comparison Statistical significance
Normal-vs-Caucasian
3.247000E-04
Normal-vs-AfricanAmerican
7.901400E-03
Normal-vs-Asian
2.715900E-03
Caucasian-vs-AfricanAmerican
8.413000E-01
Caucasian-vs-Asian
4.481800E-01
AfricanAmerican-vs-Asian
5.314600E-01
Pan-cancer view
Methylation
Survival
Correlated genes
DepMap
PAAD : Pancreatic adenocarcinoma *
Please note that low number(<10) of normal samples considered.
Note
Patient gender information is not available for 1 sample.
Show statistics
Hide statistics
Comparison Statistical significance
Normal-vs-Male
2.197400E-04
Normal-vs-Female
7.952900E-04
Male-vs-Female
1.665430E-01
Pan-cancer view
Methylation
Survival
Correlated genes
DepMap
PAAD : Pancreatic adenocarcinoma *
Please note that low number(<10) of normal samples considered.
Note
Patient age information is not available for 1 sample.
Show statistics
Hide statistics
Comparison Statistical significance
Normal-vs-Age(21-40Yrs)
7.017800E-02
Normal-vs-Age(41-60Yrs)
6.774200E-04
Normal-vs-Age(61-80Yrs)
2.424500E-04
Normal-vs-Age(81-100Yrs)
7.141300E-03
Age(21-40Yrs)-vs-Age(41-60Yrs)
4.414200E-01
Age(21-40Yrs)-vs-Age(61-80Yrs)
2.885000E-01
Age(21-40Yrs)-vs-Age(81-100Yrs)
3.023000E-01
Age(41-60Yrs)-vs-Age(61-80Yrs)
2.666800E-01
Age(41-60Yrs)-vs-Age(81-100Yrs)
2.085600E-01
Age(61-80Yrs)-vs-Age(81-100Yrs)
4.637000E-01
Pan-cancer view
Methylation
Survival
Correlated genes
DepMap
PAAD : Pancreatic adenocarcinoma *
Please note that low number(<10) of normal samples considered.
Note
Drinking status is not available for 80 samples.
Show statistics
Hide statistics
Comparison Statistical significance
Normal-vs-Non Drinker
1.966670E-04
Normal-vs-Daily Drinker
1.92543999999462E-05
Normal-vs-Weekly Drinker
4.214800E-04
Normal-vs-Occasional Drinker
1.184230E-03
Normal-vs-Social Drinker
6.044600E-03
Non Drinker-vs-Daily Drinker
2.890600E-01
Non Drinker-vs-Weekly Drinker
8.769600E-01
Non Drinker-vs-Occasional Drinker
4.037600E-01
Non Drinker-vs-Social Drinker
1.462030E-01
Daily Drinker-vs-Weekly Drinker
4.449000E-01
Daily Drinker-vs-Occasional Drinker
7.496400E-02
Daily Drinker-vs-Social Drinker
2.158400E-02
Weekly Drinker-vs-Occasional Drinker
3.888600E-01
Weekly Drinker-vs-Social Drinker
1.673030E-01
Occasional Drinker-vs-Social Drinker
5.265400E-01
Pan-cancer view
Methylation
Survival
Correlated genes
DepMap
PAAD : Pancreatic adenocarcinoma
Subtype descriptions Grade 1 Well differentiated (low grade)
Grade 2 Moderately differentiated (intermediate grade) Grade 3 Poorly differentiated (high grade)
Grade 4 Undifferentiated (high grade)
Show statistics
Hide statistics
Comparison Statistical significance
Normal-vs-Grade 1
2.745200E-01
Normal-vs-Grade 2
3.338600E-01
Normal-vs-Grade 3
5.210600E-01
Normal-vs-Grade 4
1.000000E+00
Grade 1-vs-Grade 2
4.422400E-01
Grade 1-vs-Grade 3
2.321000E-01
Grade 1-vs-Grade 4
2.745200E-01
Grade 2-vs-Grade 3
4.308400E-01
Grade 2-vs-Grade 4
3.338600E-01
Grade 3-vs-Grade 4
5.210600E-01
Pan-cancer view
Methylation
Survival
Correlated genes
DepMap
PAAD : Pancreatic adenocarcinoma *
Please note that low number(<10) of normal samples considered.
Note
Diabetes status information is not available for 30 samples.
Show statistics
Hide statistics
Comparison Statistical significance
Normal-vs-Diabetic
2.37999999999072E-05
Normal-vs-NonDiabetic
1.199230E-04
Diabetic-vs-NonDiabetic
2.540800E-01
Pan-cancer view
Methylation
Survival
Correlated genes
DepMap
PAAD : Pancreatic adenocarcinoma *
Please note that low number(<10) of normal samples considered.
Note
Pancreatitis status is not available for 39 samples.
Show statistics
Hide statistics
Comparison Statistical significance
Normal-vs-Pancreatitis
1.69423999999418E-05
Normal-vs-NoPancreatitis
1.359200E-04
Pancreatitis-vs-NoPancreatitis
1.119570E-01
Pan-cancer view
Methylation
Survival
Correlated genes
DepMap
PAAD : Pancreatic adenocarcinoma *
Please note that low number(<10) of normal samples considered.
Note
Nodal metastais status is not available for 1 sample and cancer in nearby lymph nodes cannot be measured (NX) in 4 samples.
pathologic_N descriptions N0 No regional lymph node metastasis
N1 Metastases in 1 to 3 axillary lymph nodes N2 Metastases in 4 to 9 axillary lymph nodes
N3 Metastases in 10 or more axillary lymph nodes
Show statistics
Hide statistics
Comparison Statistical significance
Normal-vs-N0
8.789200E-04
Normal-vs-N1
3.443700E-04
N0-vs-N1
9.748600E-01
Pan-cancer view
Methylation
Survival
Correlated genes
DepMap
PAAD : Pancreatic adenocarcinoma *
Please note that low number(<10) of normal samples considered.
Note
Whole exome sequencing data is not available for 3 samples.
TP53 mutation status is obtained from TCGA whole exome sequencing data. We downloaded Mutation Annotation Format (MAF) files (derived from VarScan2) from Genomic Data Commons portal. The sample with/without TP53 mutation were matched with RNA-seq data
Show statistics
Hide statistics
Comparison Statistical significance
Normal-vs-TP53-Mutant
6.768700E-04
Normal-vs-TP53-NonMutant
2.192100E-02
TP53-Mutant-vs-TP53-NonMutant
2.576700E-03
Pan-cancer view
Methylation
Survival
Correlated genes
DepMap
